Английская Википедия:AM-2201
Шаблон:Short description Шаблон:Drugbox
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor.[1] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.
Hazards
Convulsions have been reported[2] including at doses as low as 10 mg.[3]
Pharmacology
AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a Ki of 1.0 nM at CB1 and 2.6 nM at CB2.[4] The 4-methyl functional analog MAM-2201 probably has similar affinities.Шаблон:Or AM-2201 has an EC50 of 38 nM for human CB1 receptors, and 58 nM for human CB2 receptors.[5] AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, comparable to the potency of JWH-018 in rats, suggesting potent cannabinoid-like activity.[5]
Pharmacokinetics
Шаблон:See also AM-2201 metabolism differs only slightly from that of JWH-018. AM-2201 N-dealkylation produces fluoropentane instead of pentane (or plain alkanes in general).Шаблон:Citation needed
Detection
A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[6]
Legal status
In the United States, AM-2201 is a Schedule I controlled substance.[7]
See also
References
Шаблон:Cannabinoids Шаблон:Cannabinoidergics
